Antiepileptic Drugs and Switchability: Safeguarding Patients With Epilepsy in an Era of Generic Drug Substitution CME

Author Information and Disclosures

Release Date: September 30, 2008; Valid for credit through September 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Abbott: No Tagline
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Explore special considerations for pediatric epilepsy patients and ways to optimize treatment of this patient population
  2. Evaluate the risks of generic substitution and ways to prevent/manage complications
Authors and Disclosures

Barry E. Gidal, PharmD, RPh
Disclosure: Barry E. Gidal, PharmD, RPh, has disclosed that he has served as an advisor or consultant to GlaxoSmithKline, UCB, and Abbott. Dr. Gidal has also disclosed that he has received honoraria for speaking from GlaxoSmithKline, UCB, and Abbott, and has received grants for clinical research from GlaxoSmithKline and UCB.


Michelle Manzo, MPH
Disclosure: Michelle Manzo, MPH, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.